Buy PT-141 (Bremelanotide): What to Check Before You Order

PT-141growth

Cyclic heptapeptide (bremelanotide) that acts as a melanocortin receptor agonist at MC3R and MC4R in the central nervous system. The active metabolite of Melanotan-II, studied for sexual-function endpoints via a central rather than vascular pathway.

What PT-141 actually is

PT-141, generically bremelanotide, is a synthetic cyclic peptide built from seven amino acids. It comes out of the same melanocortin research programme that produced Melanotan-II, and the relationship between the two compounds is the single fact most often garbled in vendor descriptions.

Bremelanotide is not a fragment of Melanotan-II. No peptide bond is cleaved to produce it, and nothing is cut out of a larger molecule. Both compounds carry the identical seven residues arranged in the identical ring. The difference sits at one position: the C-terminal amide that Melanotan-II carries is hydrolysed to a free carboxylic acid in bremelanotide. That hydrolysis product was identified as the active metabolite of Melanotan-II, the form that persists and keeps signalling at melanocortin receptors once the parent compound has been broken down in the body. Bremelanotide, in other words, is what Melanotan-II becomes, not a piece removed from it.

That distinction matters because bremelanotide, Melanotan-II and afamelanotide get described as interchangeable in casual copy, and they are three separate entities with three separate chemistries and three separate regulatory histories. Afamelanotide is a linear thirteen-residue alpha-MSH analogue, a different length and a different structure from the cyclic seven-residue pair above; the three share a lineage, since Melanotan-II was developed by truncating and cyclising that scaffold, but they remain chemically distinct with different receptor pharmacology and regulatory status. A finding published for one of these three compounds should never be assumed to carry over to either of the other two.

What the evidence base actually is

This is worth stating plainly, because it is unusual for anything in this catalogue: bremelanotide has been through randomised, double-blind, placebo-controlled phase 3 trials, not only early-phase or preclinical work. Two identical trials, run together under a shared programme name, randomised 1267 participants; participants self-administered 1.75 mg subcutaneously on an as-needed basis over 24 weeks of treatment, and both trials met their co-primary endpoints (PMID 31599840).

Participants who completed that 24-week double-blind phase could roll into a 52-week open-label extension (PMID 31599847). That extension is worth naming carefully, because it is often cited as though it carries more weight than it does: it had no placebo arm, its analyses were descriptive rather than comparative, and attrition was heavy, with only 272 of the 684 participants who enrolled completing it. It is evidence about tolerability over a longer window, not a controlled efficacy result, and it should be read that way.

The dose range behind the phase 3 programme was established earlier. A dose-finding trial tested 0.75, 1.25 and 1.75 mg administered subcutaneously and self-selected as desired over 12 weeks (PMID 27181790), which is where 1.75 mg emerged as the dose eventually taken forward. Earlier still, a single-dose study in healthy men gave subcutaneous doses ranging from 0.3 mg up to 10 mg (PMID 14999221). The programme's earliest work was actually intranasal rather than injectable: initial pharmacokinetic and response studies used a nasal spray formulation (PMID 14963471), and a later crossover trial combined a low intranasal dose of PT-141 with a PDE5 inhibitor (PMID 15833522). Development ultimately moved to subcutaneous administration, the route the phase 3 trials and the approved product both use; the intranasal work remains part of the discovery record rather than the approved path.

The counterweight most vendors leave out

Two things separate an honest summary of bremelanotide from a marketing one: naming the independent critique of the trial data, and naming the negative animal result.

In 2021, an independent re-analysis of the phase 3 data was published (PMID 33678061). It is not a claim that the sponsor fabricated anything: the re-analysis reproduced the efficacy estimates from the original regulatory submission. Its objection concerns how the outcomes were selected and reported, the validity of the measures used to define benefit, and the balance of that benefit against harm; it specifically found a substantially higher rate of adverse-event-driven discontinuation on bremelanotide than on placebo, a detail that gets far less airtime than the topline efficacy numbers. A separate, independently authored systematic review and meta-analysis was published in 2026 (PMID 40543759), useful for the same reason: it did not originate with the company that developed the compound.

Animal research does not close ranks around a single tidy story either. A 2025 study in female Syrian hamsters mapped the MC3R and MC4R receptors onto midbrain dopamine neurons and found that bremelanotide changed neither receptor expression nor sexual reward behaviour in that model (PMID 39793696). A negative result of this kind rarely appears in vendor descriptions, which is exactly the reason to include it here.

None of this means the phase 3 result is wrong. The pivotal trials, the long-term extension and the integrated safety analysis discussed below were all sponsor-funded, with company employees among the authors, and they remain the best-controlled human data that exist for this compound. It means an honest summary places the independent critique and the negative animal finding next to the sponsor's own numbers, rather than citing only the figures that flatter the compound.

The safety numbers worth knowing before you order

The integrated safety analysis across the clinical development programme (PMID 35147466) is the single most useful safety source available here, because it pools the double-blind phase 3 population rather than reporting from one small trial in isolation. In that integrated dataset, the most frequently reported adverse events on bremelanotide, against placebo, were:

• Nausea: 40.0% versus 1.3%
• Flushing: 20.3% versus 1.3%
• Headache: 11.3% versus 1.9%
• Injection site reactions: 5.4% versus 0.5%

Nausea was the single leading reason participants stopped taking the drug in the trials. The same analysis documented transient increases in blood pressure following dosing, which is the reason the approved United States product carries a restriction against use in uncontrolled hypertension and in people with known cardiovascular disease. That restriction sits on the labelling of the approved medicine specifically; it is not a general safety note that a research material inherits automatically, because a research material is not that approved medicine.

What to check before you order

This is the part that actually protects a buyer, and it has nothing to do with how persuasive a vendor's copy sounds. Five things are worth checking on any vial before you consider ordering it.

A batch-specific certificate, not a generic one

A certificate of analysis that is not tied to the specific batch or lot printed on your vial tells you almost nothing about what is actually in that vial. A certificate worth reading shows identity confirmation, usually by mass spectrometry, chromatographic purity, and the measured content per vial in milligrams, all attached to a report number you can check directly with the testing laboratory rather than take on the seller's word alone.

Who actually commissioned the test

Say this plainly, because vendors routinely blur it: our batch documentation is produced by Janoshik, an independent analytical laboratory, and the testing is commissioned through the supply chain rather than by us. We publish the report and its reference number so it can be verified with the lab directly. We do not operate our own laboratory, and we do not describe this as independent testing that we perform ourselves, because it is not.

Content matters as much as purity

A chromatogram showing a high purity percentage says nothing about how much peptide is actually inside the vial. A vial can be genuinely that pure and still be underfilled relative to its labelled amount, which changes every downstream calculation made from it afterward. The milligram figure on the certificate, not the percentage alone, is the number a careful buyer reads first.

Storage and physical form

PT-141 ships as a lyophilised, freeze-dried powder. Sealed vials belong at 2 to 8 degrees Celsius, protected from light, before reconstitution. Once reconstituted, the solution should also be kept at 2 to 8 degrees Celsius and used within roughly four weeks. Lyophilised peptide is considerably more stable than the same peptide already in solution, which is why the powder form, rather than a pre-mixed liquid, is the standard research presentation.

Where it ships from, and what that means for customs

Shipping from inside the EU means EU customers face no US customs step and no import declaration at an external border. That changes outside the EU customs union: Norway and the United Kingdom both sit beyond it, so a shipment there crosses a customs border and travels at the buyer's own import risk, under whatever rules that destination applies to a peptide research material. That risk sits with the buyer, not with the seller, regardless of where the parcel originates.

The legal position, without false reassurance

Bremelanotide has no EU marketing authorisation. It may not be sold or administered as a medicine anywhere in the EU under that status, and being labelled for research use does not change what the underlying compound is if it ends up being used as one.

It does hold a marketing authorisation in the United States, for a specific indication in premenopausal women. That approval does not extend to the EU, and it does not extend to research material sold under this listing either: an approved medicine is a specific, regulated product with its own manufacturing chain and its own labelling, and a research peptide is not that product and is not interchangeable with it, regardless of the underlying molecule being identical.

There is no single EU-wide answer beyond that baseline fact. National rules on the sale, possession and import of unapproved, pharmacologically active substances differ between member states, and some countries apply considerably stricter rules than others. Checking those rules for your own country, before ordering, is the buyer's responsibility. It is not something a shipping address or a research-use label resolves on anyone's behalf.

Frequently asked questions

Related reading

Growth & Performancegrowth

Growth hormone secretagogues and gonadotropins

---

Research use only. The material described here is supplied strictly for in-vitro research and laboratory use. It is not intended for human or animal consumption, nor for medical, cosmetic or household applications. Nothing in this article is a dosing recommendation, a protocol, or medical advice.